Literature DB >> 498098

Enhancement of interferon antitumor action by sodium butyrate.

M F Bourgeade, I Cerutti, C Chany.   

Abstract

Sodium butyrate together with interferon enhances the antitumor effect of interferon in vivo. When Sarcoma 180 TG cells are inoculated in mice, the mean survival time and final survival rate are greatly increased compared to those for treatment with interferon alone. Similarly, a significant delay in the mean survival time is observed when mice inoculated with L1210 cells are treated with sodium butyrate and interferon. This effect could be due at least in part to a potentiation of interferon action on the tumor cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498098

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon.

Authors:  C Chany; I Cerutti
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

2.  Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.

Authors:  Sung Won Kim; Jacob M Hooker; Nicola Otto; Khaing Win; Lisa Muench; Colleen Shea; Pauline Carter; Payton King; Alicia E Reid; Nora D Volkow; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2013-07-29       Impact factor: 2.408

Review 3.  Effects of sodium butyrate, a new pharmacological agent, on cells in culture.

Authors:  J Kruh
Journal:  Mol Cell Biochem       Date:  1982-02-05       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.